Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• Non-severe aplastic anemia is a rare bone marrow failure disorder with limited data on management and outcomes.
• Characterized by variable cytopenias, its clinical and molecular features require further investigation.

Purpose of the Study:

• To analyze clinical and molecular features, treatment strategies, evolution, and survival in a large cohort of non-severe aplastic anemia patients.
• To evaluate the effectiveness of different treatment regimens and identify factors influencing patient outcomes.

Main Methods:

• A multicentric series of 259 patients with non-severe aplastic anemia were analyzed.
• Treatments included cyclosporine (CyA) alone or in combination with anti-thymocyte globulin (ATG) or eltrombopag, eltrombopag alone, or others (e.g., androgens).
• Clinical data, molecular features (NGS), and outcomes including response rates, progression, and survival were assessed.

Main Results:

• Similar 6-month overall response rates were observed across various strategies (73% for CyA to 87% for eltrombopag alone).
• A trilineage response was achieved in 39% of patients, particularly with CyA plus eltrombopag.
• Progression to myeloid neoplasms was low (8%); hemolytic paroxysmal nocturnal hemoglobinuria (PNH) developed in 10%, predicted by small PNH clones.
• Survival was negatively impacted by age, male gender, LDH, transfusion needs, and somatic mutations, but positively by neutrophils, PNH clones, and trilineage response.

Conclusions:

• Various treatment strategies for non-severe aplastic anemia yield comparable outcomes, with eltrombopag showing high efficacy.
• Achieving trilineage response and the presence of PNH clones are favorable prognostic indicators for survival.
• Age and specific clinical/molecular factors significantly influence patient survival in this rare bone marrow failure disorder.